Globus Medical Inc. Class A Common Stock (GMED)

FairStock Score: 66/100 — STEADY

Key Financials

Strengths

• Generates $328 million in annual free cash flow (2.6% yield on market cap)
• Strong Piotroski F-Score of 8/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Solid return on equity of 12.3% above cost of capital
• Conservative balance sheet with debt-to-equity of just 0.03, providing financial flexibility
• Altman Z-Score of 11.6 confirms minimal bankruptcy risk and strong solvency

Concerns

• Trades significantly above Graham Number ($55) with negative 74% margin of safety—limited downside protection

AI Analysis

Globus Medical Inc. Class A Common Stock is a mid-cap healthcare company valued at $12.8 billion. The business generates $2.9 billion in annual revenue with a 4.8% net margin and $328 million in free cash flow. From a quality standpoint, Globus shows near-perfect Piotroski F-Score of 8/9 indicating exceptional financial health and Altman Z-Score of 11.6 confirms fortress-level solvency. On valuation, the stock is reasonably priced at 24.1x earnings, with trades above its Graham Number with a negative 74% margin. Growth dynamics show revenue growing at 25.7% and profit growth of 430.4%. Our composite FairStock Score of 66/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Globus's 26% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $328 million in annual free cash flow (2.6% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer